Clinical Trial Update: Treatment of Nonalcoholic Steatohepatitis With Pioglitazone [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating pioglitazone for treatment of nonalcoholic steatohepatitis (NASH) has completed, sponsored by NIDDK.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Fatty Liver Disease
• Nonalcoholic Steatohepatitis

Drugs mentioned

• Actos (Pioglitazone)

Snippet

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Conditions: Fatty Liver, Nonalcoholic Steatohepatitis | Phase 2 | Status: COMPLETED